Tags : Hepatocellular Carcinoma (HCC)

Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study

Shot:     The P-III ORIENT-32 involves assessing of Tyvyt (sintilimab) + Byvasda (bevacizumab, biosimilar) vs sorafenib in a ratio (2:1) for 1L treatment of patients with advanced HCC The study resulted in meeting its 1EPs of PFS and OS, the safety profile is consistent with prior studies, and no new safety signals were identified. Following the […]Read More